Ludwig Enterprises appoints Garth Lees-Rolfe as independent director

LUDWIG ENTERPRISES, INC.

Garth Lees-Rolfe appointed independent director effective June 23, 2025.
Over 19 years of finance/accounting experience; currently CFO of ABLi Therapeutics.
Previously CFO of Inhibikase Therapeutics (NASDAQ: IKT) and VP Finance at F-Star (NASDAQ: FSTX).
Spent 16 years at Ernst & Young, most recently as Senior Manager; holds CPA and Chartered Accountant licenses.
No family relationships with existing directors or executive officers.

item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Garth Lees-Rolfe

Independent Director

LUDG · LUDWIG ENTERPRISES, INC.

Effective: 2025-06-23
Filed: Jun 25, 2025 23:59 UTC

On June 23, 2025, the Board appointed a new independent director, Garth Lees-Rolfe, to hold office until the earlier of the expiration of the term of office, a successor is duly elected and qualified, or the earlier of her death, resignation, disqualification, or removal.

Source: SEC EDGAR

accession 0001213900-25-057684

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.